Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Mechanism of SGLT2 Inhibition in the Kidney — Stella

Home/Type 2 Diabetes/Mechanism of SGLT2 Inhibition in the Kidney

View on ClinicalTrials.gov

Recruiting

Back to Type 2 Diabetes trials

Mechanism of SGLT2 Inhibition in the Kidney

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

University of Michigan, Ann Arbor, Michigan

Key details

Phase

Post-approval study

Sponsor

University of Michigan

Collaborators

University of Colorado, Denver, Renal Pre-Competitive Consortium (RPC3)

Enrollment target

~20 participants

Started

January 2024

Primary completion

December 2026

Age range

18 Years – 80 Years

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.